Literature DB >> 17376864

Rare cancer-specific mutations in PIK3CA show gain of function.

Marco Gymnopoulos1, Marc-André Elsliger, Peter K Vogt.   

Abstract

Fifteen rare cancer-derived mutants of PIK3CA, the gene coding for the catalytic subunit p110alpha of phosphatidylinositol 3-kinase (PI3K), were examined for their biological and biochemical properties. Fourteen of these mutants show a gain of function: they induce rapamycin-sensitive oncogenic transformation of chicken embryo fibroblasts, constitutively activate Akt and TOR-mediated signaling, and show enhanced lipid kinase activity. Mapping of these mutants on a partial structural model of p110alpha suggests three groups of mutants, defined by their location in distinct functional domains of the protein. We hypothesize that each of these three groups induces a gain of PI3K function by a different molecular mechanism. Mutants in the C2 domain increase the positive surface charge of this domain and therefore may enhance the recruitment of p110alpha to cellular membranes. Mutants in the helical domain map to a contiguous surface of the protein and may affect the interaction with other protein(s). Mutants in the kinase domain are located near the hinge of the activation loop. They may alter the position and mobility of the activation loop. Arbitrarily introduced mutations that have no detectable phenotype map either to the interior of the protein or are positioned on a surface region that lies opposite to the exposed surfaces containing gain-of-function mutants. Engineered mutants that exchange acidic or neutral residues for basic residues on the critical surfaces show a gain of function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17376864      PMCID: PMC1838453          DOI: 10.1073/pnas.0701005104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  High frequency of mutations of the PIK3CA gene in human cancers.

Authors:  Yardena Samuels; Zhenghe Wang; Alberto Bardelli; Natalie Silliman; Janine Ptak; Steve Szabo; Hai Yan; Adi Gazdar; Steven M Powell; Gregory J Riggins; James K V Willson; Sanford Markowitz; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Science       Date:  2004-03-11       Impact factor: 47.728

Review 2.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.

Authors:  Jeffrey A Engelman; Ji Luo; Lewis C Cantley
Journal:  Nat Rev Genet       Date:  2006-08       Impact factor: 53.242

Review 3.  Human tumor mutants in the p110alpha subunit of PI3K.

Authors:  Zhenning Liu; Thomas M Roberts
Journal:  Cell Cycle       Date:  2006-04-01       Impact factor: 4.534

Review 4.  mTOR and cancer therapy.

Authors:  J B Easton; P J Houghton
Journal:  Oncogene       Date:  2006-10-16       Impact factor: 9.867

5.  Characteristics of two new avian tumor virus subgroups.

Authors:  R G Duff; P K Vogt
Journal:  Virology       Date:  1969-09       Impact factor: 3.616

Review 6.  Current development of mTOR inhibitors as anticancer agents.

Authors:  Sandrine Faivre; Guido Kroemer; Eric Raymond
Journal:  Nat Rev Drug Discov       Date:  2006-08       Impact factor: 84.694

7.  The catalytic subunit of phosphoinositide 3-kinase: requirements for oncogenicity.

Authors:  M Aoki; C Schetter; M Himly; O Batista; H W Chang; P K Vogt
Journal:  J Biol Chem       Date:  2000-03-03       Impact factor: 5.157

8.  Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.

Authors:  Daniel K Broderick; Chunhui Di; Timothy J Parrett; Yardena R Samuels; Jordan M Cummins; Roger E McLendon; Daniel W Fults; Victor E Velculescu; Darell D Bigner; Hai Yan
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

9.  Structural insights into phosphoinositide 3-kinase catalysis and signalling.

Authors:  E H Walker; O Perisic; C Ried; L Stephens; R L Williams
Journal:  Nature       Date:  1999-11-18       Impact factor: 49.962

Review 10.  Mutation of the PIK3CA oncogene in human cancers.

Authors:  B Karakas; K E Bachman; B H Park
Journal:  Br J Cancer       Date:  2006-02-27       Impact factor: 7.640

View more
  164 in total

1.  Systemic epidermal nevus with involvement of the oral mucosa due to FGFR3 mutation.

Authors:  Anette Bygum; Christina R Fagerberg; Ole J Clemmensen; Britta Fiebig; Christian Hafner
Journal:  BMC Med Genet       Date:  2011-06-05       Impact factor: 2.103

Review 2.  Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

Authors:  Jiao Zhang; Yan-Hua Chen; Qun Lu
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

Review 3.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

4.  Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.

Authors:  Turgut Dogruluk; Yiu Huen Tsang; Maribel Espitia; Fengju Chen; Tenghui Chen; Zechen Chong; Vivek Appadurai; Armel Dogruluk; Agna Karina Eterovic; Penelope E Bonnen; Chad J Creighton; Ken Chen; Gordon B Mills; Kenneth L Scott
Journal:  Cancer Res       Date:  2015-12-01       Impact factor: 12.701

Review 5.  Capitalizing on tumor genotyping: towards the design of mutation specific inhibitors of phosphoinsitide-3-kinase.

Authors:  Sandra B Gabelli; Krisna C Duong-Ly; Evan T Brower; L Mario Amzel
Journal:  Adv Enzyme Regul       Date:  2010-10-28

6.  PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.

Authors:  Hiromichi Ebi; Carlotta Costa; Anthony C Faber; Madhuri Nishtala; Hiroshi Kotani; Dejan Juric; Patricia Della Pelle; Youngchul Song; Seiji Yano; Mari Mino-Kenudson; Cyril H Benes; Jeffrey A Engelman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-10       Impact factor: 11.205

7.  Membrane Recruitment as a Cancer Mechanism: A Case Study of Akt PH Domain.

Authors:  Joseph J Falke
Journal:  Cellscience       Date:  2007

8.  Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.

Authors:  Li Zhao; Peter K Vogt
Journal:  Cell Cycle       Date:  2010-02-01       Impact factor: 4.534

9.  PIK3CA somatic mutations in breast cancer: Mechanistic insights from Langevin dynamics simulations.

Authors:  Parminder K Mankoo; Saraswati Sukumar; Rachel Karchin
Journal:  Proteins       Date:  2009-05-01

10.  Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.

Authors:  Rong Wu; Suzanne J Baker; Tom C Hu; Kyle M Norman; Eric R Fearon; Kathleen R Cho
Journal:  Am J Pathol       Date:  2013-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.